TAK-881 Phase 2/3 Trial: SCIG for Primary Immunodeficiency
Examine Phase 2/3 trial results for TAK-881, a 20% SCIG therapy for primary immunodeficiency offering comparable IgG exposure in half the infusion volume.
Back to Articles
Articles tagged with “primary-immunodeficiency”